Outcome of patients with atrial fibrillation after intravenous thrombolysis for cerebral ischaemia

Journal of Neurology

Volumn 260, Issue 12, 2013, Pages 3049-3054

  Padjen, Visnja ^a,b   Bodenant, Marie ^d,e   Jovanovic, Dejana R ^a,b   Ponchelle Dequatre, Nelly ^d,e   Novakovic, Novak ^c   Cordonnier, Charlotte ^d,e   Beslac Bumbasirevic, Ljiljana ^a,b   Leys, Didier ^d,e  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c MATHEMATICAL INSTITUTE   (Serbia)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIV LILLE   (France)

Author keywords

Atrial fibrillation; Cerebral ischaemia; Haemorrhagic transformation; Ischaemic stroke; Outcome; Thrombolysis

Indexed keywords

ALTEPLASE; GLUCOSE;

ADULT; AGE; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CLINICAL PRACTICE; COMPARATIVE STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FIBRINOLYTIC THERAPY; GENERAL CONDITION DETERIORATION; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANKIN SCALE; SEX DIFFERENCE; THROMBOCYTE COUNT;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; REGISTRIES; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84890783921     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7119-4     Document Type: Article

References (39)

1. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G (2010) Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375(9727):1695-1703
2. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A (2012) The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke [the third international stroke trial (IST-3)]: a randomised controlled trial. Lancet 379(9834):2352-2363
3. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, Cohen G (2012) Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379(9834):2364-2372
4. Kimura K, Minematsu K, Yamaguchi T (2005) Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 76(5):679-683
5. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, Hommel M (1999) Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. Stroke 30(7):1326-1332
6. Lee JH, Park KY, Shin JH, Cha JK, Kim HY, Kwon JH, Oh HG, Lee KB, Kim DE, Ha SW, Cho KH, Sohn SI, Oh MS, Yu KH, Lee BC, Kwon SU (2010) Symptomatic hemorrhagic transformation and its predictors in acute ischemic stroke with atrial fibrillation. Eur Neurol 64(4):193-200
7. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB (1996) Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27(10):1760-1764
8. Larrue V, von Kummer RR, Muller A, Bluhmki E (2001) Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 32(2):438-441
9. Kimura K, Iguchi Y, Yamashita S, Shibazaki K, Kobayashi K, Inoue T (2008) Atrial fibrillation as an independent predictor for no early recanalization after IV-t-PA in acute ischemic stroke. J Neurol Sci 267(1-2):57-61
10. Murao K, Bodenant M, Cordonnier C, Bombois S, Henon H, Pasquier F, Bordet R, Leys D (2013) Does pre-existing cognitive impairment no-dementia influence the outcome of patients treated by intravenous thrombolysis for cerebral ischaemia? J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2013-305281
11. Leys D, Cordonnier C (2012) rt-PA for ischaemic stroke: what will the next question be? Lancet 379(9834):2320-2321
12. Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N, Wardlaw J, Hacke W (2009) Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol 8(12):1095-1102
13. The NINDS t-PA Stroke Study Group (1997) Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 28(11):2119-2125
14. Frank B, Fulton R, Weimar C, Shuaib A, Lees KR (2012) Impact of atrial fibrillation on outcome in thrombolyzed patients with stroke: evidence from the Virtual International Stroke Trials Archive (VISTA). Stroke 43(7):1872-1877
15. Zhang JB, Ding ZY, Yang Y, Sun W, Hai F, Sui XN, Li XY, Wang HZ, Wang XT, Zheng JL (2010) Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation. Neurol Res 32(4):353-358
16. Sung SF, Chen YW, Tseng MC, Ong CT, Lin HJ (2012) Atrial fibrillation predicts good functional outcome following intravenous tissue plasminogen activator in patients with severe stroke. Clin Neurol Neurosurg 115(7):892-895
17. Seet RC, Zhang Y, Wijdicks EF, Rabinstein AA (2011) Relationship between chronic atrial fibrillation and worse outcomes in stroke patients after intravenous thrombolysis. Arch Neurol 68(11):1454-1458
18. Kimura K, Iguchi Y, Shibazaki K, Iwanaga T, Yamashita S, Aoki J (2009) IV t-PA therapy in acute stroke patients with atrial fibrillation. J Neurol Sci 276(1-2):6-8
19. Tu HT, Campbell BC, Christensen S, Collins M, De Silva DA, Butcher KS, Parsons MW, Desmond PM, Barber PA, Levi CR, Bladin CF, Donnan GA, Davis SM (2010) Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis 30(4):389-395
20. Sanak D, Herzig R, Kral M, Bartkova A, Zapletalova J, Hutyra M, Skoloudik D, Vlachova I, Veverka T, Horak D, Kanovsky P (2010) Is atrial fibrillation associated with poor outcome after thrombolysis? J Neurol 257(6):999-1003
21. Saposnik G, Gladstone D, Raptis R, Zhou L, Hart RG (2013) Atrial fibrillation in ischemic stroke: predicting response to thrombolysis and clinical outcomes. Stroke 44(1):99-104
22. Jovanovic DR, Beslac-Bumbasirevic L, Budimkic M, Pekmezovic T, Zivkovic M, Kostic VS (2009) Do women benefit more from systemic thrombolysis in acute ischemic stroke? A Serbian experience with thrombolysis in ischemic stroke (SETIS) study. Clin Neurol Neurosurg 111(9):729-732
23. Bodenant M, Leys D, Debette S, Cordonnier C, Dumont F, Henon H, Girot M, Lucas C, Devos D, Defebvre L, Deplanque D, Leclerc X, Bordet R (2010) Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hours. Cerebrovasc Dis 30(2):148-156
24. Cordonnier C, Girot M, Dorp E, Rimetz P, Bouillaguet S, Henon H, Lucas C, Godefroy O, Leys D (2000) Stroke units from scientific evidence to practice: the experience of the Lille stroke unit. Cerebrovasc Dis 10(Suppl 4):17-20
25. Leys D, The members of the Lille stroke program (1997) Misdiagnoses in 1250 consecutive patients admitted in an acute stroke unit. Cerebrovasc Dis 7:284-288
26. Bogosavljevic V, Bodenant M, Beslac-Bumbasirevic L, Cordonnier C, Jovanovic DR, Budimkic M, Leys D (2011) Intravenous thrombolysis for acute cerebral ischemia in Belgrade, Serbia: comparison with Lille, France. Eur Neurol 66(1):30-36
27. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 333:1581-1587
28. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24(1):35-41
29. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19(5):604-607
30. Bendel R, Afifi A (1977) Comparison of stopping rules in forward regression. J Am Stat Ass 72:46-53
31. Glantz S, Slinker B (1990) Primer of applied regression and analysis of variance. McGraw Hill, New York
32. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369(9558):275-282
33. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, Roine RO, Toni D, Lees KR (2008) Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 372(9646):1303-1309
34. Hill MD, Buchan AM (2005) Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study (CASES). CMAJ 172(10):1307-1312
35. Koga M, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Okada Y, Hasegawa Y, Kario K, Okuda S, Endo K, Miyagi T, Osaki M, Minematsu K, Toyoda K (2012) Low-dose intravenous recombinant tissue-type plasminogen activator therapy for patients with stroke outside European indications: stroke acute management with urgent risk-factor assessment and improvement (SAMURAI) rtPA Registry. Stroke 43:253-255
36. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359(13):1317-1329
37. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH et al (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274(13):1017-1025
38. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352(9136):1245-1251
39. Meretoja A, Putaala J, Tatlisumak T, Atula S, Artto V, Curtze S, Happola O, Lindsberg PJ, Mustanoja S, Piironen K, Pitkaniemi J, Rantanen K, Sairanen T, Salonen O, Silvennoinen H, Soinne L, Strbian D, Tiainen M, Kaste M (2010) Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 41(7):1450-1458